Provided by Tiger Trade Technology Pte. Ltd.

INSILICO

57.600
-2.500-4.16%
Volume:4.12M
Turnover:232.69M
Market Cap:33.58B
PE:-12.86
High:57.700
Open:57.000
Low:55.700
Close:60.100
52wk High:80.900
52wk Low:29.980
Shares:583.00M
HK Float Shares:583.00M
Volume Ratio:0.34
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-4.480
ROE:--
ROA:-1.36%
PB:7.82
PE(LYR):-12.86
PS:31.68

Loading ...

Insilico Medicine Receives NMPA Approval for Clinical Trial of NLRP3 Inhibitor ISM8969/HT-001 for Parkinson's Disease

Stock News
·
Aug 03

Insilico Medicine Wins China NMPA IND Approval for Parkinson’s Drug Ism8969/ht-001

Reuters
·
Aug 03

Insilico Medicine Cayman Topco - Receives Nmpa Ind Approval for ISM8969/Ht-001

THOMSON REUTERS
·
Aug 03

Movement Alert|INSILICO Rises 5.09% in Regular Trading, ISM6331 Granted FDA Fast Track Designation Plus Sector Recovery

Market Focus
·
Jul 31

Movement Alert|INSILICO Falls 5.52% in Regular Trading, Trading at HK$40.94

Market Focus
·
Jul 30

Insilico Medicine Receives FDA Fast Track Designation for Ism6331, the Ai-Driven Pan-Tead Inhibitor, in Advanced Mesothelioma

Reuters
·
Jul 29

Insilico Medicine's Pleural Mesothelioma Drug Receives US FDA Fast Track Designation; Shares Down 4%

MT Newswires Live
·
Jul 29

Movement Alert|INSILICO Falls 5.31% in Regular Trading, ISM6331 Receives FDA Fast Track Designation But Selling Pressure Persists

Market Focus
·
Jul 29

INSILICO (03696): ISM6331 Receives FDA Fast Track Designation for Advanced Mesothelioma Treatment

Stock News
·
Jul 29

Insilico Medicine Cayman Topco - Receives FDA Fast Track Designation for Ism6331 in Advanced Mesothelioma

THOMSON REUTERS
·
Jul 29

Movement Alert|INSILICO Falls 5.07% in Regular Trading, Trading at 45.2 HKD

Market Focus
·
Jul 28

Insilico Medicine Announces Oral Presentation at Esmo 2026 for Phase 1 Clinical Study of Ism6331 in Mesothelioma and Advanced Solid Tumors

THOMSON REUTERS
·
Jul 27

INSILICO to Present First-in-Human Phase I Data for AI-Designed Pan-TEAD Inhibitor ISM6331 at ESMO 2026

Bulletin Express
·
Jul 27

Insilico Medicine Says Ism6331 Phase I Data in Mesothelioma, Advanced Solid Tumors Accepted for ESMO 2026 Rapid Oral Presentation

Reuters
·
Jul 27

Beijing's Token Economy Push and Battery Tax Shifts Reshape Market Dynamics

Stock News
·
Jul 23

INSILICO Shares Surge Over 7% Again Following Keynote at AI Conference and Major Partnership Announcements

Stock News
·
Jul 23

AI Shortens Drug Discovery to Around 1 Year in China, Insilico CEO Says

Reuters
·
Jul 23

Movement Alert|INSILICO Rises 5.46% in Regular Trading, Dense Strategic Partnerships and Sustained AI Pharma Sector Momentum

Market Focus
·
Jul 23

Movement Alert|Insilico Medicine Rises 5.47% in Regular Trading, Sector Recovery Combined with WAIC Catalyst

Market Focus
·
Jul 22

Movement Alert|Insilico Medicine Falls 5.43% in Regular Trading, Sector Pullback Compounded by Post-Lockup Investor Exit Concerns

Market Focus
·
Jul 21